Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT02661542Phase 1Completed

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Role: lead

NCT05318573Phase 2Active Not Recruiting

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Role: lead

NCT04047251Phase 1Active Not Recruiting

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

Role: lead

NCT03440450Phase 1Active Not Recruiting

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

Role: lead

NCT02454010Phase 1Completed

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Role: lead

NCT02193958Phase 1Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

Role: lead

NCT03194685Phase 1Completed

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT03486353Phase 2Withdrawn

A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

Role: lead

NCT04358549Phase 2Completed

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

Role: lead

All 9 trials loaded